Caribou Biosciences(CRBU) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update -- Two robust clinical datasets from CB-010 and CB-011 expected to be disclosed in H2 2025 -- -- $184 million in cash, cash equivalents, and marketable securities expected to fund the Company's current operating plan into H2 2027 -- BERKELEY, Calif., August 12, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, t ...